No Data
No Data
Hangzhou Minsheng Healthcare's (SZSE:301507) Returns On Capital Not Reflecting Well On The Business
Minsheng Health (301507.SZ): First-time grant of 3.32 million restricted stocks to incentive recipients.
Gelonghui, September 18th, Minsheng Health (301507.SZ) announced that on September 18, 2024, the company first granted 3.32 million restricted stocks to the participants of the restricted stock incentive plan for the year 2024 at a grant price of 6.67 yuan per share.
Minsheng Health (301507.SZ): BASF (China) as a company's procurement supplier accounts for a relatively low proportion of the total annual procurement amount.
Minsheng Health (301507.SZ) stated on the investor interaction platform on September 12th that the company's raw material procurement, supply, product production, and sales are all normal. The company's products are mostly compound preparations, which generally require multiple raw materials. Fluctuations in the price of a single raw material have little impact on the overall cost of the company's products. BASF (China), as a procurement supplier of the company, accounts for a relatively low proportion of the total annual procurement amount. The company's inventory reserves are also relatively sufficient, and it will not have a significant impact on the company's production, operation, and annual performance.
Minsheng Health (301507.SZ) 21.3933 million restricted shares will be listed for trading on September 5th.
Minsheng Health (301507.SZ) announced that the number of shares released prior to the company's initial public offering to lift restrictions this time is...
People\'s Livelihood and Health: Summary of the 2024 Semi-Annual Report
People\'s Livelihood and Health: Semi-Annual Report 2024
No Data
No Data